ROSEN, LEADING INVESTOR RIGHTS COUNSEL, Encourages StubHub Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – STUB

NEW YORK, NY / ACCESS Newswire / December 30, 2025 / The Rosen Law Firm, P.A. WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of StubHub Holdings, Inc. (NYSE:STUB) pursuant and/or traceable to the Registration Statement issued in connection with StubHub’s September 2025 initial public offering (the "IPO"), […]

Elixxer Announces Results of Annual and Special Meeting of Shareholders

Toronto, Ontario–(Newsfile Corp. – December 30, 2025) – Elixxer Ltd. (TSXV: ELXR.H) (“Elixxer” or the “Company) is pleased to announce the results of its annual and special meeting of shareholders (the “Meeting”) held on December 30, 2025. A total of 3,798,208 shares were voted at the Meeting in person or by proxy, representing 33.50% of

Burned by Stride, Inc.? Contact Levi & Korsinsky to SueWallSt And Fight Back

NEW YORK, NY / ACCESS Newswire / December 30, 2025 / – SueWallSt: Class Action Filed Against Stride, Inc. – Contact Levi & Korsinsky A Class Action lawsuit was filed on behalf of investors who lost money as a result of alleged securities fraud between October 22, 2024 and October 28, 2025. If you suffered

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. – RARE

NEW YORK CITY, NY / ACCESS Newswire / December 30, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ:RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Ultragenyx and certain of its officers and/or

Mineral Road Acquires Golcap Shares in Exchange for ROAD Shares

Vancouver, British Columbia–(Newsfile Corp. – December 30, 2025) – Mineral Road Discovery Inc. (CSE: ROAD) (the "Company" or "ROAD") announces that, further to its news release of December 22, 2025, it has issued to Mineral Road Partners Inc. ("MR Partners") an aggregate of 5,000,000 units (the "Units") at a deemed price of $0.10 per Unit

SNPS DEADLINE: ROSEN, LEADING INVESTOR RIGHTS COUNSEL, Encourages Synopsys, Inc. Investors to Secure Counsel Before Important December 30 Deadline in Securities Class Action – SNPS

NEW YORK, NY / ACCESS Newswire / December 30, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Synopsys, Inc. (NASDAQ:SNPS) between December 4, 2024 and September 9, 2025, both dates inclusive (the "Class Period"), of the important December 30, 2025 lead plaintiff deadline. SO WHAT: If

Deveron Announces Results of Special Meeting

Toronto, Ontario–(Newsfile Corp. – December 30, 2025) – Deveron Corp. (TSXV: FARM) (“Deveron” or the “Company“) is pleased to announce the results of its special meeting of shareholders (the “Meeting“) held on December 30, 2025. At the Meeting, shareholders voted in favour of all resolutions brought before the Meeting. Details of all resolutions that were

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. – ORGO

NEW YORK CITY, NY / ACCESS Newswire / December 30, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Organogenesis Holdings Inc. ("Organogenesis" or the "Company") (NASDAQ:ORGO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Organogenesis and certain of its officers and/or

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio Pharmaceuticals, Inc. – INO

NEW YORK CITY, NY / ACCESS Newswire / December 30, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Inovio Pharmaceuticals, Inc. ("Inovio" or the "Company") (NASDAQ:INO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Inovio and certain of its officers and/or

Scroll to Top